Abbott Gmbh & Co Kg

Abb Vie Deutschland Gmbh & Co. Kg

Basf Aktiengesellschaft

Abbvie Inc.

Abbott Laboratories Corporation

Other

Basf Aktienegesellschaft

Abbvie Deutschland Gmbh and Co Kg

Andreas Kling

Wilhelm Amberg

Wilfried Hornberger

Liliane Unger

Andreas Haupt

Hartmut Riechers

Dagmar Klinge

Wolfgang Wernet

Helmut Mack

Manfred Raschack

Bernd Janssen

Katja Jantos

Charles W Hutchins

Ernst Baumann

Thomas Zierke

Udo Lange

Stefan Muller

Joachim Rheinheimer

Uwe Josef Vogelbacher

Achim Moeller

Teresa Barlozzari

Kurt Ritter

Michael Ochse

Ernst Buschmann

Harald Bernard

Hervé Geneste

Marcel Van Gaalen

Astrid Netz

Berthold Behl

Gisela Backfisch

Wilfried Lubisch

Herve Geneste

Ulrich Karl

Yanbin Lao

Loic Laplanche

Volker Nimmrich

Marjoleen Nijsen

Wilfried Martin Braje

Marco Thyes

Mario Mezler

Lothar Janitschke

Sabine Schult

Bernd De Potzolli

Arnulf Lauterbach

Stefan Hergenr&ouml;der

Hans-Guenther Hege

Helmut Lietz

Francisco Javier Garcia-Ladona

Dietmar Seemann

Achim Möller

Stefan M&uuml;ller

Martina Ullrich

Francisco-Xavier Garcia-Ladona

Claudia Isabella Graef

Thomas Subkowski

Werner Seitz

Heinz Hillen

Martin Schmidt

Rolf Jansen

Johann-Christian Zechel

Jens Sadowski

Jurgen Weymann

Bernd Elger

Stefan Hergenroder

Wilfred Braje

Silke Weber

George R Pettit

Gerd Steiner

Karsten M Wicke

Michael D Williams

Rainer Schlecker

Reinhold Mueller

Cynthia A Romerdahl

Gerhard Keilhauer

Volker Laux

Barbara Vogg

Juergen Delzer

Andrea Hager-Wernet, Legal Representative

Armin Beyerbach

Uta Holzenkamp

Jayaram Kasturi Srirangam

Alfred Hahn

Stefan Mueller

Margaretha Bakker

Jayne Froggett

Kurt Schellhaas

Kieran P M Durkin

Wilfried Homberger

Jürgen Weymann

Jurgen Weyman

Thomas Subkoski

Stefan Müller

Jürgen Delzer

Ulrich Traugott

Simon Robinson

Monika De Arruda

Dietmar Seeman

Claudia Krack

The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for the treatment of vasopressin-related disorders. 

Oxindole derivatives carrying an amine-substituted piperidyl-acetidinyl substituent and use thereof for treating vasopressine-related diseases

The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders. 

Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases

The present invention relates to novel substituted oxindole derivatives of the formula I wherein A is a ring selected from phenyl and 6-membered hetaryl containing 1 or 2 nitrogen atoms as ring members, where ring A carries one substituent Rand optionally one substituent R; B is a ring selected from phenyl and a monocyclic or bicyclic heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S as ring members, where ring B may carry 1, 2 or 3 substituents R; X, X, Xand X, independently of each other, are selected from &#x2014;CH&#x2014;, &#x2014;O&#x2014;, &#x2014;S(O)&#x2014;, &#x2014;NH&#x2014;, &#x2014;C(O)&#x2014;, &#x2014;CHCH&#x2014;, &#x2014;CHO&#x2014;, &#x2014;OCH&#x2014;, &#x2014;S(O)CH&#x2014;, &#x2014;CHS(O)&#x2014;, CHNH&#x2014;, &#x2014;NHCH&#x2014;, &#x2014;CHC(O)&#x2014; and C(O)CH&#x2014;; The present invention also relates to pharmaceutical compositions comprising the novel substituted oxindole derivatives of the formula I, and to their use for the treatment of vasopressin-related disorders.

Oxindole compounds carrying a nitrogen-bound spiro substituent and use thereof for treating vasopressin-related diseases

The present invention relates to novel substituted oxindole derivatives of formula (I), pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders. 

Oxindole derivatives carrying an oxetane substituent and use thereof for treating vassopressin-related diseases

The present invention relates to novel fused heterocyclic or carbocyclic compounds of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising these compounds, and to their use for the treatment of vasopressin-related disorders.

Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases

The present invention relates to novel carboxamide compounds and their use as a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity and to a method for the therapeutic and/or prophylactic treatment by administering an effective amount of at least one of these carboxamide compounds. The carboxamide compounds are compounds of the general formula I in whichW&#x2014;Ris selected from and R, R, R, R, Y, Y, Y, Y, X, Q, m, k, Rand Rhave the meanings mentioned in the claims, the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y, Y, Yand Yare CR, or one or two of the variables Yto Yare a nitrogen atom and the remaining variables are CR, wherein the radicals Rmay be identical or different and have the meanings mentioned in the claims.

Carboxamide compounds and their use as calpain inhibitors

The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R, R, R, R, R, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R, r, R, R, R, R, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH&#x2014;CH, CH&#x2014;CH&#x2014;CH, N(R)&#x2014;CH, N(R)&#x2014;CH&#x2014;CHor CH&#x2550;CH&#x2014;CH&#x2550;, each optionally having 1 or 2H-atoms replaced with identical or different radicals R, wherein Rand Rhave the meanings mentioned in the claims.

The present invention relates to novel substituted oxindole derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising compounds I and their use for the treatment of vasopressin-related disorders.

Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases

The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors

The invention relates to the hetaryl-substituted guanidine compounds of general formula (I), enantiomeres, diastereomeres and/or tautomeres thereof, in addition to the pharmaceutically acceptable salts thereof and the prodrugs of the known compounds. The invention also relates to the use of said hetaryl-substituted guanidine compounds as binding partners for 5-HT5-receptors for treating and/or for the prophylaxis of illnesses which are modulated by a 5-HT5-receptor activity, in particular, for treating and/or for the prophylaxis of neurodegenerative and neuropsychiatric disorders, and signs, symptoms and dysfunctions associated with said disorders. 

[object Object]

The present invention relates to novel substituted oxindole derivatives of formula (I), pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders 

Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases

The present invention relates to novel carboxamide compounds of the formula I and their use for the manufacture of a medicament. The carboxamide compounds are prodrugs of inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.  

The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula (I) in which R, Rand n have the meanings mentioned in the claims and the description, Y is a radical of the formulae (Y1) or (Y2) where # indicates the point of attachment of Y to the pyridine ring, R, R, R, Rand m have the meanings mentioned in the claims and the description, A is (CH)with p being 1, 2, 3 or 4, where one or two hydrogen atoms may be replaced by a radical R, where A is attached to the 3- or 4-position of the pyrazole radical and Rhas the meaning mentioned in the claims and the description; Ais (CH)q with q being 0, 1, 2 or 3, where one or two hydrogen atoms may be replaced by halogen or C-C-alkyl; and Ais (CH)r with r being 0, 1, 2 or 3, where one or two hydrogen atoms may be replaced by halogen or C-C-alkyl, provided that that r+q is 2, 3, 4, 5 or 6; their tautomers, the hydrates thereof, the pharmaceutically suitable salts of the carbox-amide compounds (I), the prodrugs of (I) and the pharmaceutically suitable salts of the prodrugs, tautomers or hydrates of (I). 

Carboxamide compounds and their use as calpain inhibitors V

The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula I in which R, R, R, R, W, Y and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula I-A.a' and I-A.a&#x2033; in which m, E, R, R, R, R, R, Rand Rhave the meanings mentioned in the claims, n is 0, 1 or 2, the tautomers thereof and the pharmaceutically suitable salts thereof.

The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.

Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy

Growing community of inventors

Mannheim, Germany

Andreas Kling